Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Gosuranemab (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions; Therapeutic Use
- Acronyms PASSPORT
- Sponsors Biogen; Bristol-Myers Squibb
- 01 Aug 2021 Results evaluating the efficacy, safety and tolerability of gosuranemab in participants with PSP published in the Nature Medicine
- 15 Jul 2020 This trial has been discontinued in Spain.
- 15 Jul 2020 This trial has been completed in United Kingdom and Germany